share_log

Sarepta Therapeutics shares are trading higher after the company announced new results from the ongoing study of SRP-9003, the company's investigational gene therapy for limb-girdle muscular dystroph

Sarepta Therapeutics shares are trading higher after the company announced new results from the ongoing study of SRP-9003, the company's investigational gene therapy for limb-girdle muscular dystroph

Sarepta Treeutics股價上漲，此前該公司宣佈了正在進行的SRP-9003研究的新結果，SRP-9003是該公司針對四肢帶狀肌營養不良的調查性基因療法
Benzinga ·  2021/03/19 05:02

Sarepta Therapeutics shares are trading higher after the company announced new results from the ongoing study of SRP-9003, the company's investigational gene therapy for limb-girdle muscular dystrophy Type 2E.

Sarepta治療公司的股價上漲，此前該公司宣佈了正在進行的SRP-9003研究的新結果。SRP-9003是該公司針對2E型肢體帶狀肌營養不良症的調查性基因療法。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論